title: Cholinergic control over attention in rats prone to attribute incentive salience to reward cues.
abstract: Some rats [sign-trackers (STs)] are especially prone to attribute incentive salience to reward cues, relative to others [goal-trackers (GTs)]. Thus, reward cues are more likely to promote maladaptive reward-seeking behavior in STs than GTs. Here, we asked whether STs and GTs differ on another trait that can contribute to poor restraint over behavior evoked by reward cues. We report that, relative to GTs, STs have poor control over attentional performance, due in part to insufficient cholinergic stimulation of cortical circuitry. We found that, relative to GTs, STs showed poor performance on a sustained attention task (SAT). Furthermore, their performance fluctuated rapidly between periods of good to near-chance performance. This finding was reproduced using a separate cohort of rats. As demonstrated earlier, performance on the SAT was associated with increases in extracellular levels of cortical acetylcholine (ACh); however, SAT performance-associated increases in ACh levels were significantly attenuated in STs relative to GTs. Consistent with the view that the modulatory effects of ACh involve stimulation of α4β2* nicotinic ACh receptors (nAChRs), systemic administration of the partial nAChR agonist ABT-089 improved SAT performance in STs and abolished the difference between SAT-associated ACh levels in STs and GTs. Neither the nonselective nAChR agonist nicotine nor the psychostimulant amphetamine improved SAT performance. These findings suggest that individuals who have a propensity to attribute high-incentive salience to reward cues also exhibit relatively poor attentional control. A combination of these traits may render individuals especially vulnerable to disorders, such as obesity and addiction.
authors: Department of Psychology and Neuroscience Program, University of Michigan, Ann Arbor, Michigan 48109-8862, USA.
authors: Giovanna
authors: G
authors: Paolone
authors: Christopher C
authors: CC
authors: Angelakos
authors: Paul J
authors: PJ
authors: Meyer
authors: Terry E
authors: TE
authors: Robinson
authors: Martin
authors: M
authors: Sarter
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001288:Attention / Q000502:physiology*; D018679:Cholinergic Agonists / Q000494:pharmacology; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D003463:Cues; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D005260:Female; D008297:Male; D017551:Microdialysis; D009042:Motivation / Q000502:physiology*; D009538:Nicotine / Q000494:pharmacology; D025341:Principal Component Analysis; D011725:Pyridines / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012201:Reward; D013997:Time Factors; D014741:Video Recording
chemical_list: D018679:Cholinergic Agonists; D018765:Dopamine Uptake Inhibitors; D011725:Pyridines; D011759:Pyrrolidines; D009538:Nicotine; D000661:Amphetamine; C108326:pozanicline; D000109:Acetylcholine
references: Psychophysiology. 1996 Mar;33(2):175-83
references: 8851245
references: Psychopharmacology (Berl). 2012 Feb;219(3):715-25
references: 21748252
references: Brain. 2011 Jul;134(Pt 7):2013-24
references: 21690575
references: Nat Rev Neurosci. 2011 Oct 20;12(11):652-69
references: 22011681
references: Arch Gen Psychiatry. 2010 Jun;67(6):632-44
references: 20530013
references: Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
references: 8401595
references: J Neurosci. 2012 Feb 22;32(8):2886-99
references: 22357871
references: Behav Neurosci. 1999 Dec;113(6):1216-32
references: 10636300
references: Neuropharmacology. 2009;56 Suppl 1:139-48
references: 18619474
references: J Neurosci. 2013 Jan 2;33(1):214-26
references: 23283335
references: Neuropsychology. 2008 Nov;22(6):787-99
references: 18999353
references: Behav Neurosci. 2011 Dec;125(6):825-35
references: 22122146
references: Behav Brain Res. 2011 Dec 1;225(2):574-83
references: 21888929
references: Neurosci Biobehav Rev. 2010 Nov;35(2):232-47
references: 20493211
references: J Neurosci. 2008 Apr 2;28(14):3769-80
references: 18385335
references: Neuropsychopharmacology. 2007 Jul;32(7):1452-61
references: 17164812
references: J Neurosci. 2005 Apr 13;25(15):3851-6
references: 15829637
references: J Neurosci. 2009 Oct 7;29(40):12428-39
references: 19812319
references: Psychopharmacology (Berl). 2003 Jul;168(3):271-9
references: 12698230
references: Neuropsychopharmacology. 2012 May;37(6):1377-86
references: 22318198
references: Alcohol Clin Exp Res. 2010 Aug;34(8):1306-18
references: 20491734
references: J Neurosci. 2010 Mar 3;30(9):3518-30
references: 20203212
references: J Pharmacol Exp Ther. 1997 Oct;283(1):235-46
references: 9336329
references: Neuropsychopharmacology. 2007 Oct;32(10):2074-86
references: 17299502
references: J Neurosci. 2012 Apr 4;32(14):4982-91
references: 22492053
references: CNS Drug Rev. 2004 Summer;10(2):167-82
references: 15179445
references: Neuropsychopharmacology. 2011 Jan;36(1):52-73
references: 20668433
references: Brain Res. 1992 Jan 20;570(1-2):92-101
references: 1617433
references: PLoS One. 2012;7(6):e38987
references: 22761718
references: Neuropsychopharmacology. 2010 May;35(6):1391-401
references: 20147893
references: Neuropsychopharmacology. 1999 Apr;20(4):322-39
references: 10088133
references: J Neurosci. 2007 Mar 28;27(13):3477-89
references: 17392464
references: Science. 2012 Feb 3;335(6068):601-4
references: 22301321
references: Behav Brain Res. 2011 Oct 1;223(2):255-61
references: 21507334
references: Biol Psychiatry. 2009 May 15;65(10):869-73
references: 18930184
references: Biol Psychiatry. 2010 Apr 15;67(8):730-6
references: 20045508
references: Trends Cogn Sci. 2012 Jan;16(1):81-91
references: 22155014
references: Cereb Cortex. 2006 Jan;16(1):9-17
references: 15788700
references: Neuroimage. 2011 Jan 15;54(2):1518-29
references: 20851189
references: Nat Neurosci. 2012 Jan 22;15(3):358-66
references: 22267164
references: J Neurosci. 2007 Aug 1;27(31):8202-18
references: 17670967
references: J Neurosci. 2004 Aug 4;24(31):6889-97
references: 15295023
references: Nature. 2011 Jan 6;469(7328):53-7
references: 21150898
references: Eur J Neurosci. 2012 Aug;36(4):2521-32
references: 22780554
references: Brain Res Rev. 2006 Aug;51(2):145-60
references: 16530842
references: Psychopharmacology (Berl). 1999 Oct;146(4):373-90
references: 10550488
references: J Neurosci. 2013 Feb 6;33(6):2326-37
references: 23392663
references: J Pharmacol Exp Ther. 1997 Oct;283(1):247-58
references: 9336330
references: Neuron. 2007 Oct 4;56(1):141-54
references: 17920021
references: Psychopharmacology (Berl). 1995 Feb;117(3):340-57
references: 7770610
references: Drug Alcohol Depend. 2008 Sep 1;97(1-2):1-20
references: 18479844
references: Neuropsychopharmacology. 2013 Feb;38(3):405-13
references: 23032073
references: Biochem Pharmacol. 2011 Oct 15;82(8):943-51
references: 21684262
references: Schizophr Res. 2013 Mar;144(1-3):136-41
references: 23374860
references: J Neurosci. 2011 Jun 29;31(26):9760-71
references: 21715641